Product Description
Novartis was developing qcc-374, an oral PGI2 Agonist for Pulmonary Arterial Hypertension
Mechanisms of Action: PGI2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-001411-20 | P2 |
Terminated |
Hypertension, Pulmonary |
2018-11-06 |
|
| CQCC374X2201E1 | P2 |
Terminated |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2018-11-06 |
|
| 2016-001412-38 | P2 |
Terminated |
Hypertension, Pulmonary |
2018-07-11 |
|
| CQCC374X2201 | P2 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2018-06-07 |